The use ofavascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To report the results of intravitreal use of ranibizumab in a patient with macular edema due to Eales disease. Method: This was an open-label, Phase 1, 6-month study of the safety and efficacy of intravitreally administered ranibizumab in patients with macular edema due to Eales disease. A single patient was eligible for the study during the 2 years of recruitment. She received 3 monthly intravitreal injections of 0.5 mg of ranibizumab for 3 months. At each of her monthly visits during the 6-month study, she was evaluated with a full ocular examination and optical coherence tomography imaging of the macula. Primary outcome measure was change in optical coherence tomography central subfield thickness at 6 months. Results: The central macular thickness as measured on optical coherence tomography reduced from 269 mm at baseline to 186 mm at 3 months. This reduction was transient with subsequent increase to 262 mm at the conclusion of the study at 6 months. Conclusion: Ranibizumab use led to transient resolution of macular edema at 3 months; however, this reduction in edema was not sustained.

Original languageEnglish (US)
Pages (from-to)122-124
Number of pages3
JournalRetinal Cases and Brief Reports
Volume6
Issue number1
DOIs
StatePublished - Dec 2012

Fingerprint

Endothelial Growth Factors
Growth Inhibitors
Macular Edema
Optical Coherence Tomography
Intravitreal Injections
Edema
Outcome Assessment (Health Care)
Safety
Ranibizumab
Eales disease

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{9db2ace8702145ffa1f210fb9e3af225,
title = "The use ofavascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease",
abstract = "Purpose: To report the results of intravitreal use of ranibizumab in a patient with macular edema due to Eales disease. Method: This was an open-label, Phase 1, 6-month study of the safety and efficacy of intravitreally administered ranibizumab in patients with macular edema due to Eales disease. A single patient was eligible for the study during the 2 years of recruitment. She received 3 monthly intravitreal injections of 0.5 mg of ranibizumab for 3 months. At each of her monthly visits during the 6-month study, she was evaluated with a full ocular examination and optical coherence tomography imaging of the macula. Primary outcome measure was change in optical coherence tomography central subfield thickness at 6 months. Results: The central macular thickness as measured on optical coherence tomography reduced from 269 mm at baseline to 186 mm at 3 months. This reduction was transient with subsequent increase to 262 mm at the conclusion of the study at 6 months. Conclusion: Ranibizumab use led to transient resolution of macular edema at 3 months; however, this reduction in edema was not sustained.",
author = "Seema Gupta and Christina Flaxel",
year = "2012",
month = "12",
doi = "10.1097/ICB.0b013e31821608e8",
language = "English (US)",
volume = "6",
pages = "122--124",
journal = "Retinal Cases and Brief Reports",
issn = "1935-1089",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The use ofavascular endothelial growth factor inhibitor (ranibizumab) in macular edema due to eales disease

AU - Gupta, Seema

AU - Flaxel, Christina

PY - 2012/12

Y1 - 2012/12

N2 - Purpose: To report the results of intravitreal use of ranibizumab in a patient with macular edema due to Eales disease. Method: This was an open-label, Phase 1, 6-month study of the safety and efficacy of intravitreally administered ranibizumab in patients with macular edema due to Eales disease. A single patient was eligible for the study during the 2 years of recruitment. She received 3 monthly intravitreal injections of 0.5 mg of ranibizumab for 3 months. At each of her monthly visits during the 6-month study, she was evaluated with a full ocular examination and optical coherence tomography imaging of the macula. Primary outcome measure was change in optical coherence tomography central subfield thickness at 6 months. Results: The central macular thickness as measured on optical coherence tomography reduced from 269 mm at baseline to 186 mm at 3 months. This reduction was transient with subsequent increase to 262 mm at the conclusion of the study at 6 months. Conclusion: Ranibizumab use led to transient resolution of macular edema at 3 months; however, this reduction in edema was not sustained.

AB - Purpose: To report the results of intravitreal use of ranibizumab in a patient with macular edema due to Eales disease. Method: This was an open-label, Phase 1, 6-month study of the safety and efficacy of intravitreally administered ranibizumab in patients with macular edema due to Eales disease. A single patient was eligible for the study during the 2 years of recruitment. She received 3 monthly intravitreal injections of 0.5 mg of ranibizumab for 3 months. At each of her monthly visits during the 6-month study, she was evaluated with a full ocular examination and optical coherence tomography imaging of the macula. Primary outcome measure was change in optical coherence tomography central subfield thickness at 6 months. Results: The central macular thickness as measured on optical coherence tomography reduced from 269 mm at baseline to 186 mm at 3 months. This reduction was transient with subsequent increase to 262 mm at the conclusion of the study at 6 months. Conclusion: Ranibizumab use led to transient resolution of macular edema at 3 months; however, this reduction in edema was not sustained.

UR - http://www.scopus.com/inward/record.url?scp=84863015685&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863015685&partnerID=8YFLogxK

U2 - 10.1097/ICB.0b013e31821608e8

DO - 10.1097/ICB.0b013e31821608e8

M3 - Article

AN - SCOPUS:84863015685

VL - 6

SP - 122

EP - 124

JO - Retinal Cases and Brief Reports

JF - Retinal Cases and Brief Reports

SN - 1935-1089

IS - 1

ER -